PF-08098488 phase 1 trial opens recruiting for advanced solid tumors
Pfizer’s PF-08098488 is in phase 1 and recruiting for advanced solid tumors. Here’s what the registry says about the study design, timing and endpoints.
Pfizer has a phase 1 study of PF-08098488 recruiting people with advanced solid tumors, according to ClinicalTrials.gov. The registry entry was published 2026-11-16T00:00:00+00:00, and the study still has no posted results. For a general reader, that means the trial is in the early stage where researchers are still learning how the study medicine behaves in people.
The study is non-randomized and uses three experimental parts: Part 1 Dose Escalation, Part 2 Dose Expansion, and Part 2 Dose Optimization. Its primary goals focus first on Incidence of Adverse Events (AEs), then on finding a recommended monotherapy dose for expansion and a recommended monotherapy dose for further development. In plain language, the team is watching safety closely while also trying to identify a dose that can be carried forward.
"This record describes a study and its registry status; study outcomes require posted results."
How the trial is organized
The intervention listed is PF-08098488, described as a drug. The first safety window runs from the start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy, whichever comes first. That makes the safety review tightly tied to the period when participants are actually receiving the medicine.
The timing also signals that this is not a quick readout. The primary completion date is 2031-01-26, marked as ESTIMATED, so readers should treat the current entry as an active study plan rather than a finished result. The registry gives a useful snapshot of what investigators want to learn, but not an outcome.
"Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)"
What it adds to Cancer Breakthroughs
This PF-08098488 entry sits inside the active special event Cancer Breakthroughs. That context matters because it places the study alongside other cancer-related registry observations in the same live collection, including studies that are recruiting, not yet recruiting, or active not recruiting.
One nearby registry observation concerns Iparomlimab and Tuvonralimab combined with local therapy in hepatocellular carcinoma, while another looks at Vitamin D in pediatric oncology patients. They are different studies with different aims, but together they show a broad mix of cancer research activity ranging from drug studies to biology-focused work. Readers tracking the field can use that mix to see how wide the current research landscape is.